Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

Langen, K. J.; Galldiks, N.; Tonn, J. C.; Weller, M.

doi:10.1007/s11060-014-1594-z

Journal Article

FZJ-2014-04588

Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

Langen, K. J. (Corresponding Author)FZJ* ; Tonn, J. C. ; Weller, M. ; Galldiks, N.FZJ*

2014
Springer Science + Business Media B.V Dordrecht [u.a.]

Journal of neuro-oncology 120(3), 665-666 (2014) [10.1007/s11060-014-1594-z]

This record in other databases:

Please use a persistent id in citations: doi:10.1007/s11060-014-1594-z

Abstract: o the Editor,We have read with interest the review by Ryken et al. about the role of imaging in the management of progressive glioblastoma [1]. In general, we agree with this review but we cannot support the opinion that the routine use of Positron-Emission-Tomography (PET) to identify progression of glioblastoma is not recommendable.The authors have considered PET using the amino acid tracer 11C-methyl-l-methionine (MET), but the use of MET is limited to PET centers with an on-site cyclotron due the short half-life of 11C (20.4 min). In recent years, the clinical application of 18F-labeled amino acids such as O-(2-18F-fluoroethyl)-l-tyrosine (FET) or 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (FDOPA) has spread considerably due to the logistical advantages of the 18F label (half-life, 109.8 min) [2]. FET can be produced with high yields similar to the widely used FDG and distributed in a satellite concept [3]. In Europe, MET PET has been replaced in many centers by the more convenie ...

Classification: